BioSpace News Archive

Drug Development

Lilly’s Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache

A statistically significantly greater percentage of patients treated with galcanezumab also achieved at least a 50 percent reduction in weekly cluster headache attacks compared to placebo at Week 3

May 15, 2018

·

8 min read

Business

Acerus Reports First Quarter 2018 Financial Results

Product revenues increased 60% to $1.6 million versus $1.0 million in the same prior year period

May 15, 2018

·

10 min read

Business

Aldeyra Therapeutics Announces First Quarter 2018 Financial Results

Aldeyra is a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases

May 15, 2018

·

16 min read

Business

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on May 15, 2018

Palatin is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential

May 15, 2018

·

17 min read

Neovasc’s Management and Board of Directors Urge Shareholders to Vote In Favor of the Proposed Reverse Stock Split at the Upcoming Annual General and Special Meeting of Shareholders

Neovasc Inc. is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies

May 15, 2018

·

13 min read

Business

Motus GI Reports 2018 First Quarter Financial Results and Provides Business Update

Q1 2018 marked by significant corporate and clinical advancements, including successfully completing $17.5M IPO and listing on NASDAQ Capital Marke

May 15, 2018

·

9 min read

Policy

Kyros Law Announces that it is Filing Legal Claims on Behalf of Valeant Pharmaceuticals Intl Investors

Kyros Law Offices is alerting investors of Valeant that it is filling legal claims against the company for possible securities fraud violations committed by Valeant Pharmaceuticals Intl

May 15, 2018

·

2 min read

Business

Aquinnah Pharmaceuticals Appoints Travis Wager as Vice President of Research

Former Pfizer research lead to drive development of Aquinnah’s neurodegenerative therapeutic development programs

May 15, 2018

·

3 min read

Business

Accelerator Life Science Partners Broadens its Leadership Teams and Expands its Geographic Operations to San Diego and the Greater Los Angeles Area

Newly formed Operating Partners group and Clinical and Scientific Advisory Board to provide critical insights to support portfolio companies’ success and guide investment strategies

May 15, 2018

·

3 min read

Policy

UTILITY therapeutics signs license agreement with LEO Pharma A/S for US rights to mecillinam and pivmecillinam

UTILITY therapeutics Ltd (“UTILITY” or “the Company”), a pharmaceutical company focused on developing and commercialising antibiotics in the US, today announces the signature of an exclusive license agreement for the antibiotics mecillinam and pivmecillinam with LEO Pharma A/S.

May 15, 2018

·

4 min read